HIDETAKA YAKURA, MD, PhD, DPhil
Current positions:
Director, Institute for Science & Human Existence, Tokyo, Japan
Education:
1966-1972: MD, Hokkaido University School of Medicine, Sapporo, Japan
1973-1978: PhD (Pathology), Hokkaido University Graduate School of Medical Sciences, Sapporo, Japan
2007-2009: Master (Sciences humaines et sociales), LOPHISS, Université Paris 1 Panthéon-Sorbonne, sous la direction de Pr Jean Gayon
Master 1 : Réfléchir philosophiquement sur la médecine d’un point de vue canguilhémien (2008)
Master 2 : Évolution de l’approche théorique du système immunitaire (2009)2009-2016: Doctorant, Ecole Doctorale « Savoirs Scientifiques », Université Sorbonne Paris Cité - Université Paris Diderot, sous la direction de Pr Alain Leplège
Epistemological and Metaphysical Problems Posed by Immunology (Problématiques épistémologiques et métaphysiques posées par l'immunologie), soutenue le 7 décembre 2015
Positions held:
1972-1973: Hokkaido University Hospital, Sapporo, Japan
1976-1978: Postdoctoral Fellow, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
1978-1983: Staff Scientist, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
1983-1989: Assistant & Associate Professor, Department of Pathology, Asahikawa Medical College, Asahikawa, Japan
1989-2007: Director, Department of Immunology and Signal Transduction, Tokyo Metropolitan Institute for Neuroscience, Tokyo, Japan
1997-2007: Head, Molecular Research Division, Tokyo Metropolitan Organization for Medical Research, Tokyo, Japan
2013-present: Director, Institute for Science & Human Existence, Tokyo, Japan
-------------------------------------------------------------------------
1988: Visiting Scientist, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
1992-1998: Associate Scientist, National Institute of Neuroscience National Center of Neurology and Psychiatry, Tokyo, Japan
2002-2007: Adjunct Professor, Graduate School of Science, Tokyo Metropolitan University, Tokyo, Japan
2005: Professeur invité, Institut Pasteur, Paris, France, dans le laboratoire du Pr Marc Daëron
2007-2009: Associate Scientist, Tokyo Metropolitan Organization for Medical Research, Tokyo, Japan
2016-2018: Invited Investigator, François Rabelais University, Tours, France
Papers
Yakura H (2020) Immunity in light of Spinoza and Canguilhem. Philosophies 5: 38
Yakura H (2020) Cognitive and memory functions in plant immunity. Vaccines 8: 541
Yakura H (2019) Response to Fred Keijzer’s comments. Adaptive Behavior 27: 179-180 <manuscript>
Yakura H (2019) A hypothesis: CRISPR-Cas as a minimal cognitive system. Adaptive Behavior 27: 167-173
Yakura H (2014) La médecine avec la vie contemplative. THE LUNG perspectives 22: 107-110 (en japonais)
Harumiya S, Yoshino A, Hayashizaki K, Mizuno K, Yakura H, Adachi T (2013) A system for reconstructing B cell antigen receptor signaling in the mouse myeloma J558L cell line. Arch Biochem Biophys 533: 18-24
Yakura H (2013) Philosophical problems in neuropsychology. Jpn J Neuropsychology 29: 35-43 (in Japanese)
Yakura H & Shimaoka M (2013) Un dialogue. Etudier à l’étranger comme une pratique des arts libéraux. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 245: 1043-1053 (en japonais)
Yakura H (2011) A “thought collective” around the idiotype network theory. BioEssays 33: 552-554
Nakata K, Suzuki Y, Inoue T, Ra C, Yakura H & Mizuno K (2011) Deficiency of SHP1 leads to sustained and increased ERK activation in mast cells, thereby inhibiting IL-3-dependent proliferation and cell death. Mol Immunol 48: 472–480
Akimoto M, Mishra K, Lim K-T, Tani N, Hisanaga S, Katagiri T, Elson A, Mizuno K & Yakura H (2009) Protein tyrosine phosphatase ε is a negative regulator of FcεRI-mediated mast cell responses. Scand J Immunol 69: 401-411
Nakata K, Yoshimaru T, Suzuki Y, Inoue T, Ra C, Yakura H & Mizuno K (2008) Positive and negative regulation of high affinity IgE receptor-signaling by Src homology region 2 domain-containing phosphatase 1. J Immunol 181: 5414-5424
Ozawa T, Nakata K, Mizuno K & Yakura H (2007) Negative autoregulation of Src homology region 2-domain-containing phosphatase 1 in rat basophilic leukemia-2H3 cells. Int Immunol 19: 1049-1061
Mizuno K, Tagawa Y, Watanabe N, Ogimoto M & Yakura H (2005) SLP-76 is recruited to CD22 and dephosphorylated by SHP-1, thereby regulating B cell receptor-induced c-Jun N-terminal kinase activation. Eur J Immunol 35: 644-654
Ogimoto M, Ichinowatari G, Watanabe N, Tada N, Mizuno K & Yakura H (2004) Impairment of B cell receptor-mediated Ca2+ influx, activation of mitogen-activated protein kinases and growth inhibition in CD72-deficient BAL-17 cells. Int Immunol 16: 971-982
Shrivastava P, Katagiri T, Ogimoto M, Mizuno K & Yakura H (2004) Dynamic regulation of Src-family kinases by CD45 in B cells. Blood 103: 1425-1432
Mizuno K, Tagawa Y, Mitomo K, Watanabe N, Katagiri T, Ogimoto M & Yakura H (2002) Src homology region 2 domain-containing phosphatase 1 positively regulates B cell receptor-induced apoptosis by modulating association of B cell linker protein with Nck and activation of c-Jun NH2-terminal kinase. J Immunol 169: 778-786
Adachi T, Wienand J, Wakabayashi C, Yakura H, Reth M & Tsubata T (2001) SHP-1 requires inhibitory co-receptors to down-modulate B cell antigen receptor-mediated phosphorylation of cellular substrates. J Biol Chem 276: 26648-26655
Arimura Y, Ogimoto M, Mitomo K, Katagiri T, Yamamoto K, Volarevic S, Mizuno K & Yakura H (2001) CD45 is required for CD40-induced inhibition of DNA synthesis and regulation of c-Jun NH2-terminal kinase and p38 in BAL-17 B cells. J Biol Chem 276: 8550-8556
Ogimoto M, Arimura Y, Katagiri T, Mitomo K, Woodgett JR, Nebreda AR, Mizuno K & Yakura H (2001) Opposing regulation of B cell receptor induced activation of mitogen activated protein kinases by CD45. FEBS Lett 490: 97-101
Kumanogoh A, Watanabe C, Lee I, Wang X, Shi W, Araki H, Hirata H, Iwahori K, Uchida J, Yasui T, Matsumoto M, Yoshida K, Yakura H, Pan C, Parnes JR & Kikutani H (2000) Identification of CD72 as a lymphocyte receptor for the class IV semaphorin CD100: A novel mechanism for regulating B cell signaling. Immunity 13: 621-631
Mizuno K, Tagawa Y, Mitomo K, Arimura Y, Hatano N, Katagiri T, Ogimoto M & Yakura H (2000) Src homology 2 (SH2) domain-containing phosphatase-1 dephosphorylates B cell linker protein/SH2 domain leukocyte protein of 65 kDa and selectively regulates c-Jun NH2-terminal kinase activation in B cells. J Immunol 165: 1344-1351
Uetani N, Kato K, Ogura H, Mizuno K, Kawano K, Mikoshiba K, Yakura H, Asano M & Iwakura Y (2000) Impaired learning with enhanced hippocampal long-term potentiation in PTP-deficient mice. EMBO J 19: 2775-2785
Adachi T, Wakabayashi C, Yakura H & Tsubata T (1999) CD72 negatively regulates signaling through the antigen receptor of B cells. J Immunol 164: 1223-1229
Katagiri T, Ogimoto M, Hasegawa K, Arimura Y, Mitomo K, Okada M, Clark MR, Mizuno K & Yakura H (1999) CD45 negatively regulates Lyn activity by dephosphorylating both positive and negative regulatory tyrosine residues in immature B cells. J Immunol 163: 1321-1326
Hasegawa K, Yajima H, Katagiri T, Ogimoto M, Arimura Y, Mitomo K, Mashima K, Mizuno K & Yakura H (1999) Requirement of PEST domain tyrosine phosphatase PEP in B cell antigen receptor-induced growth arrest and apoptosis. Eur J Immunol 29: 887-896
Adachi T, Flaswinkel H, Yakura H, Reth M & Tsubata T (1998) The B cell surface protein CD72 recruits the tyrosine phosphatase SHP-1 upon tyrosine phosphorylation. J Immunol 160: 4662-4665
Mizuno K, Katagiri T, Maruyama E, Hasegawa K, Ogimoto M & Yakura H (1997) SHP-1 is involved in neuronal differentiation of P19 embryonic carcinoma cells. FEBS Lett 417: 6-12
Nomura T, Han H, Howard MC, Yagita H., Yakura H, Honjo T & Tsubata T (1996) Antigen receptor-mediated B cell death is blocked by signaling via CD72 or treatment with dextran sulfate and is defective in autoimmunity-prone mice. Int Immunol 8: 867-875
Mizuno K, Katagiri T, Hasegawa K, Ogimoto M & Yakura H (1996) Hematopoietic cell phosphatase, SHP-1, is constitutively associated with the SH2 domain-containing leukocyte protein, SLP-76, in B cells. J Exp Med 184: 457-463
Katagiri T, Ogimoto M, Hasegawa K, Mizuno K & Yakura H (1995) Selective regulation of Lyn tyrosine kinase by CD45 in immature B cells. J Biol Chem 270: 27987-27990
Ogimoto M, Katagiri T, Mashima K, Hasegawa K, Mizuno K & Yakura H (1995) Antigen receptor-initiated growth inhibition is blocked in CD45-loss variants of a mature B lymphoma, with limited effects on apoptosis. Eur J Immunol 25: 2265-2271
Ariyama T, Hasegawa K, Inazawa J, Mizuno K, Ogimoto M, Katagiri T & Yakura H (1995) Assignment of the human protein tyrosine phosphatase, receptor-type, zeta (PTPRZ) gene to chromosome band 7q31.3. Cytogenet Cell Genet 70: 52-54
Mizuno K, Hasegawa K, Ogimoto M, Katagiri T & Yakura H (1994) Developmental regulation of gene expression for the MPTPdelta isoforms in the central nervous system and the immune system. FEBS Lett 355: 223-228
Ogimoto M, Katagiri T, Mashima K, Hasegawa K, Mizuno K & Yakura H (1994) Negative regulation of apoptotic death in immature B cells by CD45. Int Immunol 6: 647-654
Ogimoto M, Katagiri T, Hasegawa K, Mizuno K & Yakura H (1993) Induction of CD45 isoform switch in murine B cells by antigen receptor stimulation and by phorbol myristate acetate and ionomycin. Cell Immunol 151: 97-109
Mizuno K, Hasegawa K, Katagiri T, Ogimoto M, Ichikawa T & Yakura H (1993) MPTP, a putative murine homolog of HPTP, is expressed in specialized regions of the brain and in the B-cell lineage. Mol Cell Biol 13: 5513-5523
Hasegawa K, Ariyama T, Inazawa J, Mizuno K, Ogimoto M, Katagiri T & Yakura H (1993) Chromosomal assignment of the gene for protein tyrosine phosphatase HPTPdelta. Jpn J Cancer Res 84: 1219-1222
Ogimoto M, Mizuno K, Tate G, Takahashi H, Katagiri M, Hasegawa K & Yakura H (1992) Regulation of lipopolysaccharide- and IL-4-induced immunoglobulin heavy chain gene activation: differential roles for CD45 and Lyb-2. Int Immunol 4: 651-659
Ashida T, Kubo K, Kawabata I, Katagiri M, Ogimoto M & Yakura H (1990) Signal transduction mechanisms of Ia induction in B cells by interleukin 4 and immunoglobulin receptors. Cell Immunol 126: 233-238
Kobata T, Yagita H, Matsuda H, Tansyo S, Yakura H, Katagiri M & Okumura K (1990) A novel homodimeric molecule involved in human T cell activation. J Immunol 144: 830-835
Daita G, Yonemasu Y, Ishikawa M, Shimizu T & Yakura H (1989) Intracranial malignant teratoma diagnosed in a fetus. Neurol Med Chir 29: 1026-1029
Yakura H, Ashida T, Kawabata I & Katagiri M (1989) Alleviation of autoimmunity in BXSB mice by monoclonal alloantibody to Ly-5 (CD45). Eur J Immunol 19: 1505-1508
Ashida T, Yakura H, Kawabata I, Murakami M & Katagiri M (1988) Structural features of the Lyb-2 molecule. Immunogenet 28: 286-288
Yakura H, Kawabata I, Ashida T, Shen FW & Katagiri M (1986) A role for Lyb-2 in B cell activation mediated by a B cell stimulatory factor. J Immunol 137: 1475-1481
Yakura H, Kawabata I, Shen FW & Katagiri M (1986) Selective inhibition of lipopolysaccharide-induced IgG response by monoclonal Ly-5 antibody. J Immunol 136: 2729-2733
Yakura H, Shen FW, Bourcet E & Boyse EA (1983) On the function of Ly-5 in the regulation of antigen-driven B cell differentiation. Comparison and contrast with Lyb-2. J Exp Med 157: 1077-1088
Yakura H, Shen FW, Bourcet E & Boyse EA (1982) Evidence that Lyb-2 is critical to specific activation of B cells before they become responsive to T cell and other signals. J Exp Med 155: 1309-1316
Yakura H, Shen FW, Kaemmer M & Boyse EA (1981) Lyb-2 system of mouse B cell. Evidence for a role in the generation of antibody-forming cells. J Exp Med 153: 129-135
Yakura H, Shen FW, Boyse EA & Tang L (1980) The Lyb-2 phenotype of hemolytic PFC. Immunogenet 10: 603-605
Sasazuki T, McMichael A, Payne R, McDevitt HO, Yakura H, Wakisaka A, Aizawa M & Itakura K (1977) An HLA-D specificity found in the Japanese population. Tissue Antigens 9: 62-65
Yakura H, Wakisaka A, Aizawa M, Itakura K, Tagawa Y & Sugiura S (1976) HLA-D antigen of Japanese origin (LD-Wa) and its association with Vogt-Koyanagi-Harada syndrome. Tissue Antigens 8: 35-42
Wagatsuma Y, Yakura H, Nakayama E, Wakisaka A, Aizawa M, Miyata M, Matsuyama R, Sato M & Itakura K (1976) Inheritance of asthma in families and its linkage to HLA haplotypes. Acta Allergol 31: 455-462
Tagawa Y, Sugiura S, Yakura H, Wakisaka A, Aizawa M & Itakura K (1976) HLA and Vogt-Koyanagi-Harada syndrome. N Eng J Med 295: 173
Yakura H, Wakisaka A, Fujimoto S & Itakura K (1974) Hereditary ataxia and HL-A genotypes. N Eng J Med 291: 154-155
Nakayama E, Itakura K, Yakura H, Aizawa M, Kuroda M & Hanada K (1974) Sa 1, a possible new HL-A specificity found in the Japanese population. Vox Sang 27: 134-140
Reviews
Yakura H (1998) Phosphatases and kinases in lymphocyte signaling. Immunol Today 19: 198-2016
Yakura H (1994) The role of protein tyrosine phosphatases in lymphocyte activation and differentiation. Crit Rev Immunol 14: 311-336
Shen FW, Yakura H & Tung JS (1982) Some compartments of B cell differentiation. Immunol Rev 69: 69-80
Itakura K, Yakura H, Nakayama E & Aizawa M (1975) HL-A and MLC antigens in the Japanese population. Keio J Med 24: 377-391
Books
Yakura H (2023) From Immunity to Science as Philosophy. Misuzu Shobo, Tokyo, Japan
Yakura H (2022) In Search of a New Ethics of Knowledge: A Meditative Life of an Immunologist in Paris. Ishiyaku Publishers, Tokyo, Japan
Tamura S, Yakura H, Takeda S, Miyamoto E (editors) (2000) Structure and Function of Protein Phosphatases. Kyoritsu Shuppan, Tokyo, Japan
Yakura H (editor) (1997) Kinases and Phosphatases in Lymphocyte and Neuronal Signaling. Springer-Verlag, Tokyo, Japan
Pascale Cossart, La nouvelle microbiologie. Des microbiotes aux CRISPR. Odile Jacob, 2016 (Misuzu Shobo, to be published in March 2019)
Philippe Kourilsky, Le Jeu du hasard et de la complexité. La nouvelle science de l’immunologie. Odile Jacob, 2014 (Misuzu Shobo, June 19, 2018)
Essais « Un regard de Paris sur ce monde » (en japonais)
(105) Au-delà d'un voyage dans le patrimoine de l’humanité. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 280: 1200-1203, 2022
(104) Mémorandum pour le problème de "science et religion." Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 280: 184-187, 2022
(103) Faisons de la "métaphysicalisation de la science" une culture, et pourquoi est-ce encore "l'esprit scientifique" ? Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 279: 759-763, 2021
(102) Mon chemin d'Edgar Morin, un centenaire, et la philosophie naturelle comme mon voie. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 278: 1007-1010, 2021
(101) "Virtue epistemology," ou un rôle pour la métaphysicalisation de la science. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 27: 180-183, 2021
(100) Rétrospective du voyage au patrimoine de l'humanité. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 277: 507-510, 2021
(99) Théétète de Platon, ou qu'est-ce que savoir ? Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 276: 1085-1088, 2021
(98) Métaphysique de l'immunité, ou penser avec Spinoza. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 276: 177-180, 2021
(97) Immunité des plantes, son mécanisme de reconnaissance et de mémoire. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 275: 853-856, 2020
(96) Le panpsychisme moderne, ou ses problèmes et ses possibilités. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 275: 311-314, 2020
(95) Le panpsychisme, peut-il surmonter le physicalisme ? Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 274: 1149-1152, 2020
(94) CRISPR-Cas, ou ce qui nous amène au panpsychisme. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 274: 623-626, 2020
(93) La pandémie de Covid-19, ou penser l'avant et l'après. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 274: 237-240, 2020(92) La pandémie de Covid-19, ou ce qu'un observateur a vu. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 273: 1115-1118, 2020
(91) Traité de la réforme de l'entendement, ou un poteau indicateur menant vers une compréhension du monde et vers une vie heureuse. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 273: 615-618, 2020
(90) Surmonter la modernité, ou la réflexion sur la science et la situation intellectuelle japonaises par les japonais. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 273: 203-206, 2020
(89) La technique d'Oswald Spengler, ou existe-t-il un moyen d'échapper au sort de la civilisation moderne ? Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 272: 1171-1174, 2020
(88) Voltaire et Rousseau, ou les deux pôles pour réflechir sur le 21e siècle. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 272: 563-566, 2020
(87) Un regard de La Nouvelle microbiologie de Pascale Cossart sur ce monde, et le langage des sciences. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 272: 194-197, 2020
(86) Qu'est-ce que la métaphysique ? et repenser son rôle dans la science. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 271: 1255-1258, 2019
(85) Le flux d'information dans des organismes vivants, ou est-il possible de définir l'information ? Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 271: 625-628, 2019
(84) Le philosophe Michel Serres, ou ce que signifie "construire un pont." Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 271: 226-230, 2019
(83) Lucien Jerphagnon, ou ce que signifie "vivre dans l'Antiquité". Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 270: 1099-1102, 2019
(82) Edwin O. Wilson, ou l'altruism dans le mond biologique. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 270: 586-590, 2019
(81) L'existence humaine selon Heidegger, ou ce que signifie "devenir un véritable être humain". Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 270: 211-214, 2019
(80) La science et la métaphore, ou la médecine pour Platon. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 269: 830-833, 2019
(79) CRISPR-Cas, ou repenser la hérédité des caractères acquis. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 269: 506-509, 2019
(78) CRISPR-Cas, ou ce qui unit le systeme immunitaire et le systeme nerveuex. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 269: 179-183, 2019
(77) La maladie et le cosmopolitanisme, ou le remaniement de la normativité de la vie. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 268: 884-887, 2019
(76) Un équilibre entre la quotidienneté et la spiritualité, ou la tradition de la philosophie antique à faire revivre maintenant. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 268: 536-540, 2019
(75) Réfléchir aux problèmes de la médecine moderne au symposium "Humain en Médecine". Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 268: 166-170, 2019
(74) « Technè » selon Heidegger, ou penser aux temps modernes d'un point de vue technique. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 267: 800-804, 2018
(73) Le climat et l'être humain, ou choisir une terre. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 267: 488-492, 2018
(72) Paracelse, ou sa philosophie naturelle et l'alchimie. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 267 : 176-180, 2018
(71) Le premier chirurgien, Ambroise Paré, ou la philosophie de la guérison et la vitalité incroyable. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 266 : 815-819, 2018
(70) Le temps du silence, ou ce qui vous fait vous-même. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 266 : 184-187, 2018
(69) Hans-Georg Gadamer, ou dialoguer et comprendre. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 265 : 911-915, 2018
(68) Traduire, ou l'écrivain Édouard Glissant. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 265 : 539-543, 2018
(67) Paul Kammerer et William Summerlin, ou ce qui déforme la science. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 265 : 182-186, 2018
(66) Phédon de Platon, ou penser l’éternité de l’âme. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 264 : 930-934, 2018
(65) De la vie méditative à la vie réflexive, ou une transition vers un nouvel équilibre intérieur. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 264 : 562-566, 2018
(64) Les Lumières et Les anti-Lumières, ou ce qui nous divise. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 264 : 202-206, 2018
(63) Ernst Haeckel, ou la recherche de la connaissance, l’éthique, et la beauté monistes. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 263 : 886-890, 2017
(62) Le chemin vers la vérité absolue, ou le premier pas, consiste-t-il à être conscient de chaque expérience de la vie ? Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 263 : 551-555, 2017
(61) Marcel Conche, ou la vie d’un philosophe. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 263 : 211-215, 2017
(60) La méditation et la vie en France, et imaginer ses effets. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 262 : 1062-1065, 2017
(59) Épictète et Marc Aurèle, et le stoïcisme vivant dans les temps modernes. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 262 : 750-754, 2017
(58) La civilisation, la culture, et la science. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 261 : 1123-1127, 2017
(57) La philosophie de la vie en France moderne, et quelle est la situation de philosopher ? Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 261 : 1123-1127, 2017
(56) « L’autrui dans le soi », ou l’homme libre, Hokusai, et l’homme universel, Hirata Atsutane. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 261 : 778-782, 2017
(55) L’organisme, ou « tu dois changer ta manière de voir ». Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 261 : 204-208, 2017
(54) L’existence des plantes, ou ce qui signifie « voir ». Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 260 : 934-938, 2017
(53) La théorie de la vie de Tolstoï, la critique de la science, et Metchnikoff. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 260 : 550-554, 2017
(52) La science comme culture, ou la pratique de la « métaphysicalisation de la science ». Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 260 : 187-191, 2017
(51) Diogène, ou ce que signifie « parler franchement ». Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 259 : 1168-1171, 2016
(50) La recherche qui a commencé dans une nouvelle ville, et un espace qui s’etend et se connecte. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 259 : 811-815, 2016
(49) La soutenance, et « être étudiant ». Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 259 : 205-209, 2016
(48) La « religion de l’humanité » de Auguste Comte, ou l’esprit de la « métaphysicalisation de la science ». Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 258 : 1085-1089, 2016
(47) Ce que le détroit de Douvres sépare, ou la philosophie analytique et la philosohie continentale. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 258 : 815-819, 2016
(46) La « Troisième couche de la conscience », ou le « divertissement » de Pascal. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 258 : 185-189, 2016
(45) Attendez d’être né au lieu de le faire, ou la « negative capability ». Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 257 : 1187-1191, 2016
(44) Ma relation avec les langues étrangères, ou pourquoi les apprendre ? Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 257 : 803-807, 2016
(43) Pierre Hadot, ou la « conversion philosophique ». Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 257 : 193-197, 2016
(42) « Difficile à imiter la forme, mais facille à imiter le sens », ou le langage de la science. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 256 : 1179-1183, 2016
(41) Le sentiment philosophique, ou où voyez-vous le Tout du monde ? Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 256 : 847-851, 2016
(40) Le réseau du mode par défaut, ou ce que signifie « être distrait ». Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 256 : 178-182, 2016
(39) Le cheminement vers « ma vérité », ou penser avec le patrimoine de l’humanité. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 255 : 1140-1144, 2015
(38) La commutation de la mémoire, ou de l’événement à la création. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 255 : 787-791, 2015
(37) Le médecin de l’âme, Epicure: sa philosophie et sa vie. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 252 : 839-839, 2015
(36) Une recherche dans le forêt de la mémoire, ou l’exercice de penser. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 252 : 209-213, 2015
(35) « Définir la vie » au Muséum national d’histoire naturelle. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 251 : 1099-1103, 2014
(34) La guérison selon Georges Canguilhem, ou la confiance en la vie. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 251 : 525-529, 2014
(33) La téléologie est-elle vraiment une nuisance de la science ? Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 251 : 199-202, 2014
(32) Repenser la métaphysicalisation de la science à Lille. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 250 : 1063-1068, 2014
(31) L’Éthique et la morale, et les sciences humaines et sociales dans la formation médicale. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 250 : 529-533, 2014
(30) L’Atopie et la philosophie, et ce que Montaigne a essayé. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 250 : 165-169, 2014
(29) Penser la temporalité de la vie et de la biomédecine à Roscoff. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 249 : 1211-1215, 2014
(28) Regarder le monde de la biosémiotique à Manhattan, et repenser la relation entre la science et la philosophie. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 249 : 565-569, 2014
(27) La vie ou la liberté, ou la fin de vie dans la dignité. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 249 : 202-206, 2014
(26) Christian de Duve, ou l’honnêteté intellectuelle. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 248 : 811-815, 2014
(25) La philosophie de la médecine à Paris, à Roscoff, et à New York. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 248 : 491-495, 2014
(24) La postérité, a-t-elle vengé Lamarck? et l’impression d’Israël. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 248 : 174-178, 2014
(23) Réfléchir à Lamarck et à l’évolution en Israël. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 247 : 1193-1197, 2013
(22) Découvrir Escher à La Haye, et penser au monde de Spinoza. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 247 : 577-581, 2013
(21) De la science du XVIIe siècle au voyage de la fécondité et de la joie en Hollande. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 247 : 213-217, 2013
(20) La « negative capability » de John Keats, ou la capacité de rester dans l’incertitude. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 246 : 989-993, 2013
(19) La science conçue par Sir Richard Roberts et le professeur Kazu Kurosawa. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 246 : 522-526, 2013
(18) La vie d’Alexandre Yersin, le découvreur du bacille de la peste, et Shibasaburo Kitasato. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 246 : 201-205, 2103
(17) L’Energeia d’Aristote ou le temps de Julian Barbour. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 245: 895-899, 2013
(16) Giordano Bruno, un moine, philosophe et scientifique, et son magnifique univers. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 245 : 541-545, 2013
(15) Jacques Benveniste de la « mémoire de l’eau» et Luc Montagnier. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 245 : 203-206, 2013
(14) Ce qui unit Ōgai Mori et Paul Ehrlich. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 244 : 944-947, 2013
(13) La science pour le XXIe siècle, ou une nouvelle éthique du savoir. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 244 : 572-576, 2013
(12) Penser l’éducation de la philosophie à la Journée mondiale de la philosophie. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 244 : 196-199, 2013
(11) La pangenèse de Darwin, ou l’explication que la science exige. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 243 : 929-933, 2012
(10) Les deux centenaires, Ernst Mayr et Sewall Wright, ou un regard de 100 ans. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 243 : 551-554, 2012
(9) Ludwik Fleck, un chercheur philosophique oublié, et la sociologie des sciences. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 243 : 203-206, 2012
(8) François Jacob, ou la science doit-elle avoir une inclination philosophique ? Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 242 : 832-836, 2012
(7) Niel Jerne, un scientifique philosophique de l’Europe. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 242 : 559-563, 2012
(6) L’Esprit de Dr William Clark, ou ce qui est derrière la réception de la science moderne au Japon. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 242 : 213-216, 2012
(5) Réfléchir avec le Pr. Philippe Kourilsky sur la relation entre la spécialité et la responsabilité. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 241 : 802-805, 2012
(4) L’Éducation de la philosophie dans une université française, ou réfléchir sur ce que signifie « être enraciné dans sa propre culture ». Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 241 : 486-490, 2012
(3) Le vitaliste montpelliérain, Paul-Joseph Barthez, ou le monde où flotte le passé. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 241 : 171-174, 2012
(2) L’Immunité innée, ou Élie Metchnikoff et Jules Hoffmann. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 240 : 837-840, 2012
(1) De la science à la philosophie, ou un voyage dans le patrimoine de l’humanité. Igaku-no-ayumi (Journal of Clinical and Experimental Medicine) 240 : 549-552, 2012
2019.6.8: "Philosophizing immunity", Plenary Lecture, 190e Société Franco-Japonaise de Biologie, Tokyo Women's Medical University, Tokyo, Japan
2019.4.20: "Cognition viewed from immunity", Special lecture, Open Forum for the "Ontology of György Lukács", Chuo University, Tokyo, Japan
2019.2.14: "Immunity and cognition", Centre Cavaillès, École normale supérieure, Paris, France
2017.10.18: “Towards a metaphysics of immunity”, Research Institute for Medical Sciences, Tokyo University of Science, Chiba, Japan
2016.9.26 : « Vers une métaphysique de l’immunité », UFR de sciences et techniques, Université François Rabelais, Tours, France
2016.10.31: “Studying philosophy of science in Paris”, Nara Women’s University, Nara, Japan
2014.11.19: “Science & philosophy, and immunity & memory in life”, Research Institute for Medical Sciences, Tokyo University of Science, Chiba, Japan
2013.9.13: “Reflecting on a new ethics of knowledge”, Nurture of Creative Research Leaders Program, Chiba University, Chiba, Japan
2013.9.12: “Science through the lens of philosophy”, Nara Women’s University, Nara, Japan
2013.9.9: “Think about how to utilize philosophy for medicine and science”, Tokyo Medical University, Tokyo, Japan
2012.12.6: “Explaining immunity”, The 41th Meeting of the Japanese Society of Immunology, Kobe, Japan
2012.12.2: “Science for the 21st century -- A view from philosophy”, Kobe University School of Medicine, Kobe, Japan
2012.9.14: “Philosophical problems in neuropsychology”, The 36th Annual Meeting of Neuropsychology Association Japan, Tokyo, Japan
2012.9.13: “Why is philosophy needed to science?”, National Institute for Infectious Diseases, Tokyo, Japan
2012.4.23: “What philosophy can contribute to science, or science and two breeds of philosophy”, Advanced Seminar Series on Microbiology & Immunology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
2012.4.20: “A role for philosophy in science & medicine”, Tokushima University Faculty of Medicine, Tokushima, Japan
2011.11.29: “Think about system, the whole and the parts, and emergence”, The 40th Meeting of the Japanese Society of Immunology, Chiba, Japan
2011.7.27: “Reflect on life sciences from philosophy of science”, Tokyo Interdisciplinary Life Science Consortium, Tokyo Medical & Dental University, Tokyo, Japan
2011.7.21: “Do we need philosophy in science?”, Molecular Pathology Seminar, Hokkaido University School of Medicine, Sapporo, Japan
2011.2.9: “Thoughts on immunity from the interface of science and philosophy”, Advanced Seminar Series on Microbiology & Immunology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
2009.12.2: “Science without philosophy, or what science can benefit from philosophy”, The 39th Meeting of the Japanese Society of Immunology, Osaka, Japan
2009.8.5: “What is an ideal life scientist?”, Tokyo Metropolitan Institute for Neuroscience, Tokyo, Japan
2009.7.29: “What is philosophy for scientists?”, Molecular Pathology Seminar, Hokkaido University School of Medicine, Sapporo, Japan
2008.11.13: “The phosphotyrosine signaling system: A view from the other side”, The 8th International Conference on Protein Phosphatases, Maebashi, Japan
2005.7.4 : « Régulation de l’activation des lymphocytes et des mastocytes par protéine-tyrosine phosphatases », Hôpital Necker-Enfants Malades - Paris V, Paris, France
2005.6.28 : « Régulation de l’activation des lymphocytes et des mastocytes par protéine-tyrosine phosphatases », l’Institut de Signalisation et Innovation Thérapeutique - Université Paris-Sud XI., Châtenay-Malabry, France
2005.6.23: « Regulation of lymphocyte and mast cell signaling by tyrosine phosphatases », Institut Pasteur, Paris, France
2002: “Regulation of two biological systems by protein tyrosine phosphatases”, Tokyo University of Agriculture and Technology, Tokyo, Japan
2001: “Role of protein tyrosine phosphatases in lymphocyte signaling”, Institut Pasteur, Paris, France
2001: “Regulation of lymphocyte signaling by protein tyrosine phosphatases”, University of Rijeka, Rijeka, Croatia
2001: “Regulation of lymphocyte signaling by CD45”, McGill Cancer Centre, McGill University, Montreal, Canada
2000: “Lymphocyte signaling and tyrosine phosphatases”, Asahikawa Medical College, Asahikawa, Japan
1999: “Protein tyrosine phosphatases in lymphocyte signal transduction”, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
1999: “Protein tyrosine phosphatases in B cell fate determination”, University of Texas MD Anderson Cancer Center, Houston, USA
1999: “Protein tyrosine phosphatases regulating B cell receptor signaling”, Pennsylvania State University College of Medicine, Hershey, USA
1999: “Protein tyrosine phosphatases that determine lymphocyte fate”, Indiana University School of Medicine, Indianapolis, USA
1999: “Regulatory mechanisms of tyrosine phosphatases in lymphocyte signal transduction”, Institute of Immunological Science, Hokkaido University, Sapporo, Japan
1998: “The role of protein tyrosine phosphatases in lymphocyte signaling”, Institute of Molecular and Cell Biology, National University of Singapore, Singapore
1998: “Regulation of the immune system by protein tyrosine phosphatases”, National Institute for Basic Biology, Okazaki, Japan
1998: “Protein tyrosine phosphatases in lymphocyte signaling”, Research Laboratory, Otsuka America Pharmaceutical, Inc., Bethesda, USA
1998: “Regulation of lymphocyte signal transduction by tyrosine phosphatases”, Institute of Development, Aging, and Cancer, Tohoku University, Sendai, Japan
1998: “Lymphocyte signal transduction and protein tyrosine phosphatases”, Okayama University School of Medicine, Okayama, Japan
1997: “Protein tyrosine phosphatases and B cell signal transduction”, Institute of Immunology, University of Heidelberg, Heidelberg, Germany
1997: “Protein tyrosine phosphatases in B lymphocyte signaling”, Max-Planck Institute for Immunobiology, Freiburg, Germany
1997: “Protein tyrosine phosphatases in BCR signal transduction”, Basel institute for Immunology, Basel, Switzerland
1997: “Regulation of lymphocyte signaling by protein tyrosine phosphatases”, Friedrich Miescher Institute, Basel, Switzerland
1997: “Signal transduction of B lymphocytes and protein tyrosine phosphatases”, Otsuka Pharmaceutical Co., Tokushima, Japan
1997: “Mechanisms of B cell activation”, Faculty of Pharmaceutical Sciences, Osaka University, Osaka, Japan
1997: “Regulation of B cell signaling by protein tyrosine phosphatases”, Babraham Institute, Cambridge, UK
1995: “Regulation of B cell signal transduction by protein tyrosine phosphatases”, University of Iowa College of Medicine, Iowa City, USA
1994: “Regulation of the immune system by protein tyrosine phosphatases”, Institute of Immunological Science, Hokkaido University, Sapporo, Japan
1994: “Regulation of lymphocyte activation by protein tyrosine phosphatases”, Institute of Medical Science, University of Tokyo, Tokyo, Japan
1992: “Receptor-type protein tyrosine phosphatases expressed in the immune and central nervous systems”, National Jewish Center for Immunology and Respiratory Medicine, Denver, USA
1992: “Regulation of immune and nervous systems by receptor-type protein tyrosine phosphatases”, Asahikawa Medical College, Asahikawa, Japan
1991: “Regulatory mechanisms of B lymphocyte differentiation by CD45, a protein tyrosine phosphatase, and Lyb-2”, University of Texas MD Anderson Cancer Center, Houston, USA
1991: “Regulation of B cell differentiation by Lyb-2 and a transmembrane tyrosine phosphatase CD45”, University of Miami School of Medicine, Miami, USA
1989: “B cell activation and immunological abnormalities”, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan
1989: “Regulation of antibody class by differentiation antigens and its clinical relevance”, Institute of Immunology, Johannes Gutenberg University, Mainz, Germany
1989: “Regulation of antibody class switch and treatment of autoimmune disorders”, Allergy Consortium, Chiba University, Chiba, Japan
1984: “Regulatory mechanisms of B cell differentiation and potential therapeutic strategies for autoimmune diseases”, Institute of Immunological Science, Hokkaido University, Sapporo, Japan
1984: “Differentiation antigens that regulate B cell differentiation”, Clinical Research Centre, Harrow, UK
1982: “Mechanisms of B lymphocyte activation”, State University of New York, Stony Brook, USA
1982: “Mechanisms of lymphocyte differentiation mediated by B cell differentiation antigens”, Institute of Immunology, Chiba University, Chiba, Japan
1982: “Regulation of B cell differentiation by non-immunoglobulin allotypic molecules”, Downstate Medical Center, State University of New York, Brooklyn, USA
1978: “Role of T lymphocytes in the immune response to Listeria monocytogenes”, Harvard Medical School, Boston, USA
Aucun commentaire:
Enregistrer un commentaire